ArticleHNO2026
[The 9th edition of the UICC Cancer Staging Manual : Updates in otorhinolaryngology, head and neck surgery].
Article in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe TNM system, implemented since 1958, is an established tool for classifying solid tumors and categorizing them based on tumor size and extent, regional lymph node involvement, and the presence of distant metastases. The current 9th edition of the TNM system offers extensive revisions in the head and neck area, with a particular focus on the clinical, radiological, and pathological extracapsular spread of lymph node metastases and the corresponding prognostic relevance. MATERIALS AND
methodsThe 9th edition of the TNM classification of the Union for International Cancer Control (UICC) served as the basis for the review. It was published in July 2025 and should be implemented from January 2026. The background to the corresponding changes is explained based on a detailed literature search.
resultsAs before, revisions to the TNM classification were made particularly for human papillomavirus (HPV)/p16-positive oropharyngeal cancers with regard to extracapsular extension. For nasopharyngeal cancers, there was a modification to the UICC stages due to improved prognostic significance. Specifications were also made for the depth of invasion of oral cavity cancers. Minor salivary gland cancers have now been included in the classification system alongside cancers of major salivary glands.
conclusionFollowing extensive revisions in the head and neck area, there have been notable changes, particularly in the field of HPV/p16-positive oropharyngeal cancer. The extent to which these changes will prove to be prognostically relevant remains to be seen after the new TNM system has been implemented in clinical routine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.